Diabetes

Top Story

Twice-daily aspirin may confer CV benefit in type 2 diabetes

Twice-daily aspirin may confer CV benefit in type 2 diabetes
September 18, 2017

Patients with type 2 diabetes but without existing cardiovascular disease experienced a time-dependent increase in platelet aggregation in the 24 hours after once-daily aspirin therapy, suggesting that a twice-daily aspirin regimen could provide CV benefit, study data show.

“The antiplatelet effects of aspirin do not last for the standard 24-hour dosing interval, and patients with type 2 diabetes have alterations in their platelet function,” Liv Vernstrøm, a master’s student in the department of endocrinology and internal medicine at Aarhus University in Denmark, told Endocrine Today. “Perhaps the alterations seen in platelet function in patients with type 2 diabetes could be related to their increased risk for CVD. Further, they might benefit from an alternative dosing regimen when it comes to treatment with aspirin. Our data indicate that a twice-daily dosing could add additional benefits, but this needs to be studied further.”

AADE: Telehealth should be included in Medicare Diabetes Prevention Program

September 18, 2017
The American Association of Diabetes Educators outlined several recommendations for a CMS proposal to include the Medicare Diabetes Prevention Program in the 2018…
Meeting News

DEVOTE: Hypoglycemia, glycemic variability increase mortality risk in type 2 diabetes

September 15, 2017
In adults with type 2 diabetes, higher day-to-day fasting glycemic variability and severe hypoglycemia are independently associated with all-cause mortality, according…
Meeting News

CV death risk decreases with evolocumab in atherosclerotic disease

September 15, 2017
The risks for cardiovascular death, myocardial infarction and stroke are reduced in adults with atherosclerotic disease with or without diabetes treated with the PCSK9…
More Headlines »
Advertisement
Advertisement